Hemangioma Treatment Market Size by Type, Diagnosis, Treatment, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2027

3.5%
CAGR (2021-2027)
268.26 USD Mn.
Market Size
326
Report Pages
160
Market Tables

Overview

Global Hemangioma Treatment Market is expected to reach US$ 341.30 Mn by 2027 from US$ 268.26 Mn in 2020, at a CAGR of 3.5 % during forecast period.

Global Hemangioma Treatment Market Overview:

A Hemangioma is a bright red a birthmark that appears at birth or during the first two weeks after birth. A hemangioma can appear anywhere on the body, but they're most common on the face, scalp, chest, and back. Hemangioma is a benign or non-cancerous blood vessel tumour that appears as a rubbery bump on the skin.

Global Hemangioma Treatment Market

Global Hemangioma Treatment Market Dynamics:

Rising prevalence of Hemangioma is expected to majorly drive the market growth.

Globally, the prevalence of hemangioma in infants is around 5% to 10% suffering from this disease. Girls, premature babies, twins, and triplets are the most common victims of this disease, and it is most common in Caucasians. The research studies state that spinal hemangioma affects about 10% of the world's population, necessitating further care. Spinal hemangioma is most common in people between the ages of 30 and 50, and it sometimes goes unnoticed. During the forecast period, the market is expected to be fuelled by proper diagnosis and an increase in minimally invasive procedures for removing tumors found in the body's internal organs. The increase in the number of cases being reported each day across the world, as well as the introduction of improved care options, are factors that could contribute to a high growth rate in the coming years. The industry is also expected to make substantial gains as more drugs are used and medication therapies are used. Moreover, ongoing technological advancements, raising awareness about the disease, and rising investment in research and development of new treatment options are expected to aid the market growth.

However, certain factors are expected to hamper the market growth. The side effects associated with surgical laser procedures, high cost for the treatment of hemangioma and strict approval policies are anticipated to hinder the market growth.

The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Hemangioma Treatment Market Segment Analysis:

The Global Hemangioma Treatment Market is segmented on the basis of Type, Diagnosis and Treatment.

Based on type, the infantile hemangioma segment is expected to dominate the global market during the forecast period. Hemangiomas in children are benign vascular neoplasms that involve early proliferation and spontaneous involution. Hemangiomas are the most common tumors in children, and they are typically medically unimportant. The prevalence of infantile hemangioma is 4-5%, and the rise in the prevalence of hemangioma, especially in non-hispanic white female babies, may drive the infantile hemangioma market.

Based on the treatment, the beta-blocker drugs segment is expected to hold a larger market share as it is the commonly used medication. The beta-blockers segment consists of drugs such as propranolol, timolol, atenolol, nadolol. A gel containing the drug timolol may be applied to the infected skin in case of superficial hemangiomas. If treated with an oral solution of propranolol, a serious infantile hemangioma can disappear.

Global Hemangioma Treatment Market

To know about the Research Methodology :- Request Free Sample Report

Global Hemangioma Treatment Market Regional Insights:

North America holds the dominant market share.

North America region is expected to continue the dominance during the forecast period. Due to a higher number of minimally invasive procedures, an increase in infantile hemangioma, and an increase in adult hemangioma cases, North America is expected to dominate the global hemangioma treatment market during the forecast period. Another factor driving the market in North America is the presence of key players in the area who provide a variety of oral and topical medications for the treatment of hemangioma. Followed by North America, Europe holds the second largest market share. An increase in research and development projects is expected to aid market growth.

The report also helps in understanding Global Hemangioma Treatment Market dynamics, structure by analyzing the market segments and project the Global Hemangioma Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Hemangioma Treatment Market make the report investor’s guide.

Global Hemangioma Treatment Market Scope:
Inquire before buying

Global Hemangioma Treatment Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 268.26 Mn.
Forecast Period 2021 to 2027 CAGR: 3.5% Market Size in 2027: US $ 341.30 Mn.
Segments Covered: by Type • Infantile Hemangioma
• Capillary Hemangioma
• Cavernous Hemangioma
• Others
by Diagnosis • X Ray
• Computerized Tomography (CT) Scans
• Biopsy
• Others
by Treatment • Corticosteroid Medication
• Laser Surgery
• Beta Blocker Drugs
• Others

Global Hemangioma Treatment Market, By Region:

• North America
• Europe
• South America
• MEA
• APAC

Global Hemangioma Treatment Market, Key players

• Pierre Fabre
• AstraZeneca
• BIOLASE, Inc.
• Quanta System S.p.A.
• Pfizer, Inc. (U.S.)
• Cutting Edge Laser Technologies
• Novartis AG
• Linline Medical Systems
• Akrimax Pharmaceuticals, LLC.
• Bausch Health
• Cutera
• Teva Pharmaceutical Industries Ltd
• IRIDEX Corporation
• Alma Lasers Ltd
• AbbVie Inc.

Table of Contents

1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Hemangioma Treatment Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Hemangioma Treatment Market 3.4. Geographical Snapshot of the Hemangioma Treatment Market, By Manufacturer share 4. Global Hemangioma Treatment Market Overview, 2020-2027 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Hemangioma Treatment Market 5. Supply Side and Demand Side Indicators 6. Global Hemangioma Treatment Market Analysis and Forecast, 2020-2027 6.1. Global Hemangioma Treatment Market Size & Y-o-Y Growth Analysis. 7. Global Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 7.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 7.1.1. Infantile Hemangioma 7.1.2. Capillary Hemangioma 7.1.3. Cavernous Hemangioma 7.1.4. Others 7.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 7.2.1. X Ray 7.2.2. Computerized Tomography (CT) Scans 7.2.3. Biopsy 7.2.4. Others 7.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 7.3.1. Corticosteroid Medication 7.3.2. Laser Surgery 7.3.3. Beta Blocker Drugs 7.3.4. Others 8. Global Hemangioma Treatment Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2020-2027 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 9.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 9.1.1. Infantile Hemangioma 9.1.2. Capillary Hemangioma 9.1.3. Cavernous Hemangioma 9.1.4. Others 9.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 9.2.1. X Ray 9.2.2. Computerized Tomography (CT) Scans 9.2.3. Biopsy 9.2.4. Others 9.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 9.3.1. Corticosteroid Medication 9.3.2. Laser Surgery 9.3.3. Beta Blocker Drugs 9.3.4. Others 10. North America Hemangioma Treatment Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 11.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 11.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 11.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 12. Canada Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 12.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 12.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 12.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 13. Mexico Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 13.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 13.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 13.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 14. Europe Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 14.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 14.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 14.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 15. Europe Hemangioma Treatment Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 16.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 16.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 16.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 17. France Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 17.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 17.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 17.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 18. Germany Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 18.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 18.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 18.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 19. Italy Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 19.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 19.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 19.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 20. Spain Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 20.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 20.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 20.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 21. Sweden Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 21.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 21.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 21.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 22. CIS Countries Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 22.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 22.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 22.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 23. Rest of Europe Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 23.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 23.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 23.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 24. Asia Pacific Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 24.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 24.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 24.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 25. Asia Pacific Hemangioma Treatment Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 26.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 26.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 26.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 27. India Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 27.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 27.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 27.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 28. Japan Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 28.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 28.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 28.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 29. South Korea Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 29.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 29.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 29.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 30. Australia Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 30.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 30.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 30.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 31. ASEAN Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 31.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 31.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 31.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 32. Rest of Asia Pacific Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 32.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 32.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 32.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 33. Middle East Africa Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 33.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 33.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 33.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 34. Middle East Africa Hemangioma Treatment Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 35.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 35.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 35.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 36. GCC Countries Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 36.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 36.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 36.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 37. Egypt Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 37.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 37.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 37.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 38. Nigeria Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 38.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 38.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 38.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 39. Rest of ME&A Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 39.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 39.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 39.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 40. South America Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 40.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 40.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 40.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 41. South America Hemangioma Treatment Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 42.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 42.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 42.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 43. Argentina Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 43.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 43.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 43.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 44. Rest of South America Hemangioma Treatment Market Analysis and Forecasts, 2020-2027 44.1. Market Size (Value) Estimates & Forecast By Type, 2020-2027 44.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2020-2027 44.3. Market Size (Value) Estimates & Forecast By Treatment, 2020-2027 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Hemangioma Treatment Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Pierre Fabre 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. AstraZeneca 45.3.3. BIOLASE, Inc. 45.3.4. Quanta System S.p.A. 45.3.5. Pfizer, Inc. (U.S.) 45.3.6. Cutting Edge Laser Technologies 45.3.7. Novartis AG 45.3.8. Linline Medical Systems 45.3.9. Akrimax Pharmaceuticals, LLC. 45.3.10. Bausch Health 45.3.11. Cutera 45.3.12. Teva Pharmaceutical Industries Ltd 45.3.13. IRIDEX Corporation 45.3.14. Alma Lasers Ltd 45.3.15. AbbVie Inc. 46. Primary Key Insights